The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | Considering age and disease characteristics in the risk stratification and management of WM
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses the key factors influencing the risk of disease progression and mortality in patients with Waldenström’s macroglobulinemia (WM), emphasizing that older patients are at higher risk. He also mentions key features of the disease itself that are used to categorize patients into high-risk and low-risk groups for more tailored management. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
ADC Therapeutics: Research Funding; Pfizer: Research Funding; AstraZeneca: Research Funding; Affimed: Research Funding; Takeda: Research Funding; SeaGen: Research Funding; BMS: Research Funding; Regeneron Pharmaceuticals, Inc.: Research Funding.
